Mohamed Ezzat M. Mansour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamed Ezzat M. Mansour has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Omar Kassar
Faculty of Medicine, Alexandria University, Alexandria, Egypt
4 shared publications Ahmed Ezzat Elmetwalli
Faculty of Medicine, Misr University for Science and Technology, Giza, Egypt
3 shared publicationsKhalid Radwan Alsaadany
Faculty of Medicine, Mansoura University, Mansoura, Egypt
3 shared publications- Khalid Radwan Alsaadany
Faculty of Medicine, Mansoura University, Mansoura, Egypt
3 shared publications Mohamed Awad E. Ahmed
Faculty of Medicine, Suez University, Suez, Egypt
3 shared publications- Mohamed Awad E. Ahmed
Faculty of Medicine, Suez University, Suez, Egypt
3 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Efficacy and safety of theta-burst stimulation for obsessive-compulsive disorder: a systematic review and meta-analysis
- 18 August 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessEfficacy and safety of theta-burst stimulation for obsessive-compulsive disorder: a systematic review and meta-analysis
- Open Access
- 11 May 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1) , 384
N-acetylcysteine for patients with alcohol use disorder, post-traumatic stress disorder, and their co-occurrence: a systematic review of placebo-controlled randomized trials
Introduction: Alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) are thought to be significant global contributors to the burden of mental illness. According to recent WHO epidemiological estimates, 3.9% of people worldwide have experienced PTSD at some point in their lives; this number rises to roughly 5.6% among those who have experienced trauma. NAC has shown promise in reducing PTSD symptoms and cravings in veterans, according to recent trials. Our analysis aims to resolve the conflict between results and determine whether NAC is an effective add-on therapy for PTSD, AUD, and co-occurring PTSD/AUD. Methods: We conducted this study in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, following our protocol (CRD420251170956). We searched PubMed, Scopus, Cochrane CENTRAL, Embase, EBSCO, and the Web of Science for relevant studies. Only randomized placebo-controlled trials were included. The primary outcomes were severity of PTSD and alcohol craving, while secondary outcomes were anxiety, depression, and alcohol use patterns and biomarkers. Results: Seven randomized, double-blind, placebo-controlled trials were included in this meta-analysis, enrolling a total of 566 participants. There were no significant differences between NAC and placebo in craving (SMD= -0.40, 95% CI [-1.05, 0.25], P = 0.22, I² = 56.1%). Regarding PTSD severity, the PCL scale pooled analysis demonstrated no significant difference between NAC and placebo (SMD = 0.04, 95% CI [-0.40, 0.48], P = 0.8) (I² = 65.9%, P = 0.05), while the CAPS scale pooled analysis demonstrated no significant difference between NAC and placebo (SMD = -0.13, 95% CI [-0.50, 0.24], P = 0.49) (I² = 54.8%, P = 0.109). Leave-one-out sensitivity analysis showed that exclusion of the Back et al. (2025) study resulted in a significant effect favoring NAC (SMD = -0.35, 95% CI [-0.70, -0.01], P = 0.04), with no observed heterogeneity (I² = 0%). Conclusion: Our meta-analysis indicates that N-acetylcysteine, when compared to placebo, does not demonstrate consistent efficacy in reducing the primary symptoms of AUD or PTSD in broad patient populations. However, the treatment is relatively safe. A noteworthy signal of potential efficacy for PTSD symptoms emerged in a sensitivity analysis, suggesting that the therapeutic promise of NAC should not be entirely dismissed. Clinical trial number: Not applicable.
- 11 May 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1) , 384
Open AccessN-acetylcysteine for patients with alcohol use disorder, post-traumatic stress disorder, and their co-occurrence: a systematic review of placebo-controlled randomized trials
Introduction: Alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) are thought to be significant global contributors to the burden of mental illness. According to recent WHO epidemiological estimates, 3.9% of people worldwide have experienced PTSD at some point in their lives; this number rises to roughly 5.6% among those who have experienced trauma. NAC has shown promise in reducing PTSD symptoms and cravings in veterans, according to recent trials. Our analysis aims to resolve the conflict between results and determine whether NAC is an effective add-on therapy for PTSD, AUD, and co-occurring PTSD/AUD. Methods: We conducted this study in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, following our protocol (CRD420251170956). We searched PubMed, Scopus, Cochrane CENTRAL, Embase, EBSCO, and the Web of Science for relevant studies. Only randomized placebo-controlled trials were included. The primary outcomes were severity of PTSD and alcohol craving, while secondary outcomes were anxiety, depression, and alcohol use patterns and biomarkers. Results: Seven randomized, double-blind, placebo-controlled trials were included in this meta-analysis, enrolling a total of 566 participants. There were no significant differences between NAC and placebo in craving (SMD= -0.40, 95% CI [-1.05, 0.25], P = 0.22, I² = 56.1%). Regarding PTSD severity, the PCL scale pooled analysis demonstrated no significant difference between NAC and placebo (SMD = 0.04, 95% CI [-0.40, 0.48], P = 0.8) (I² = 65.9%, P = 0.05), while the CAPS scale pooled analysis demonstrated no significant difference between NAC and placebo (SMD = -0.13, 95% CI [-0.50, 0.24], P = 0.49) (I² = 54.8%, P = 0.109). Leave-one-out sensitivity analysis showed that exclusion of the Back et al. (2025) study resulted in a significant effect favoring NAC (SMD = -0.35, 95% CI [-0.70, -0.01], P = 0.04), with no observed heterogeneity (I² = 0%). Conclusion: Our meta-analysis indicates that N-acetylcysteine, when compared to placebo, does not demonstrate consistent efficacy in reducing the primary symptoms of AUD or PTSD in broad patient populations. However, the treatment is relatively safe. A noteworthy signal of potential efficacy for PTSD symptoms emerged in a sensitivity analysis, suggesting that the therapeutic promise of NAC should not be entirely dismissed. Clinical trial number: Not applicable.
- 9 January 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 107, 106980
Exposure to tobacco smoke during pregnancy and the risk of multiple sclerosis in offspring: A systematic review and meta-analysis
- 9 January 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 107, 106980
Exposure to tobacco smoke during pregnancy and the risk of multiple sclerosis in offspring: A systematic review and meta-analysis
- 24 December 2025
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (4) , 621-631
Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 55 clinical trials
Introduction: Schizophrenia is a severe mental disorder that impacts thoughts, emotions, and behavior, affecting 0.32% of the global population. While antipsychotic medications are crucial for managing symptoms, nearly half of individuals with schizophrenia experience weight gain, leading to treatment non-compliance and further health complications. Our systematic review and network meta-analysis aim to provide comprehensive evidence on the safety and efficacy of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain. Methods: We conducted this study in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, following our protocol (CRD42024599597). We searched PubMed, Scopus, Web of Science, and Cochrane Library until July 2025. Only randomized placebo-controlled trials were included. We focused on anthropometric measurements and safety profiles. The primary outcome was weight change, while the secondary outcomes included waist-hip ratio, waist circumference, and hip circumference. Result: Fifty-five studies were included in the meta-analysis, with a total of 2977 individuals. Regarding the weight change, the highest three interventions hold the highest probability of being the most effective therapy in weight loss compared to the Usual care group were Semagultide (MD: −13.5 [−17.3, −9.57], followed by Metformin + NutriEx (MD: −6.34, [−9.85, −2.9]), then Nizatidine (MD: −5.46 [−7.77, −2.76]). According to non-pharmacological interventions, all interventions showed significant reductions in weight ( p -value < 0.05). Conclusion: We found that Semaglutide has the highest probability of being the most effective therapy in the reduction of weight gain and BMI. Liraglutide was associated with mild adverse effects. Additional trials focusing on non-pharmacological approaches are essential.
- 24 December 2025
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (4) , 621-631
Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 55 clinical trials
Introduction: Schizophrenia is a severe mental disorder that impacts thoughts, emotions, and behavior, affecting 0.32% of the global population. While antipsychotic medications are crucial for managing symptoms, nearly half of individuals with schizophrenia experience weight gain, leading to treatment non-compliance and further health complications. Our systematic review and network meta-analysis aim to provide comprehensive evidence on the safety and efficacy of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain. Methods: We conducted this study in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, following our protocol (CRD42024599597). We searched PubMed, Scopus, Web of Science, and Cochrane Library until July 2025. Only randomized placebo-controlled trials were included. We focused on anthropometric measurements and safety profiles. The primary outcome was weight change, while the secondary outcomes included waist-hip ratio, waist circumference, and hip circumference. Result: Fifty-five studies were included in the meta-analysis, with a total of 2977 individuals. Regarding the weight change, the highest three interventions hold the highest probability of being the most effective therapy in weight loss compared to the Usual care group were Semagultide (MD: −13.5 [−17.3, −9.57], followed by Metformin + NutriEx (MD: −6.34, [−9.85, −2.9]), then Nizatidine (MD: −5.46 [−7.77, −2.76]). According to non-pharmacological interventions, all interventions showed significant reductions in weight ( p -value < 0.05). Conclusion: We found that Semaglutide has the highest probability of being the most effective therapy in the reduction of weight gain and BMI. Liraglutide was associated with mild adverse effects. Additional trials focusing on non-pharmacological approaches are essential.
- Open Access
- 3 November 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 1-12
Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials
Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; p = 0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; p = 0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RR = 0.68; 95% CI: 0.49 to 0.95; p = 0.02). The study provides initial insights into sulforaphane’s potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.
- 3 November 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 1-12
Open AccessEfficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials
Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; p = 0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; p = 0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RR = 0.68; 95% CI: 0.49 to 0.95; p = 0.02). The study provides initial insights into sulforaphane’s potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.
- 19 December 2024
- Published by Springer Nature in Psychopharmacology
- Vol. 242 (1) , 45-62
Safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including GRADE qualifications
Introduction Attention-deficit/hyperactivity disorder (ADHD) is a complex neurodevelopmental disorder. It is one of the most common mental disorders in youth worldwide characterized by persistent overactivity and impulsivity/inattention symptoms associated with social and academic impairment. dasotraline has been suggested to play a pivotal role as a serotonin, norepinephrine, and dopamine reuptake inhibitor. This study aimed to create evidence from published randomized clinical trials (RCTs) about the benefits of dasotraline for ADHD patients. Methods A computer literature search (PubMed, Scopus, Web of Science, and Cochrane CENTRAL) was conducted. We included RCTs comparing dasotraline versus placebo. The primary outcome measure was the ADHD Rating Scale-IV score, pooled as the mean difference between the two groups from baseline to the endpoint. The secondary outcome measures were the ADHD Rating Scale-IV Inattention score, ADHD Rating Scale-IV Hyperactivity score. Results Five RCTs with a total of 1594 patients were included in this study. dasotraline showed a significant improvement in the primary outcome (MD –2.65, 95% CI [–4.14 to –1.17], P= 0.0004 Conclusion The results showed that dasotraline demonstrated a significant improvement in both primary and secondary outcomes, establishing its efficacy as a novel treatment for ADHD symptoms. However, mild to moderate side effects were observed.
- 19 December 2024
- Published by Springer Nature in Psychopharmacology
- Vol. 242 (1) , 45-62
Safety and efficacy of dasotraline for patients with attention deficit/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including GRADE qualifications
Introduction Attention-deficit/hyperactivity disorder (ADHD) is a complex neurodevelopmental disorder. It is one of the most common mental disorders in youth worldwide characterized by persistent overactivity and impulsivity/inattention symptoms associated with social and academic impairment. dasotraline has been suggested to play a pivotal role as a serotonin, norepinephrine, and dopamine reuptake inhibitor. This study aimed to create evidence from published randomized clinical trials (RCTs) about the benefits of dasotraline for ADHD patients. Methods A computer literature search (PubMed, Scopus, Web of Science, and Cochrane CENTRAL) was conducted. We included RCTs comparing dasotraline versus placebo. The primary outcome measure was the ADHD Rating Scale-IV score, pooled as the mean difference between the two groups from baseline to the endpoint. The secondary outcome measures were the ADHD Rating Scale-IV Inattention score, ADHD Rating Scale-IV Hyperactivity score. Results Five RCTs with a total of 1594 patients were included in this study. dasotraline showed a significant improvement in the primary outcome (MD –2.65, 95% CI [–4.14 to –1.17], P= 0.0004 Conclusion The results showed that dasotraline demonstrated a significant improvement in both primary and secondary outcomes, establishing its efficacy as a novel treatment for ADHD symptoms. However, mild to moderate side effects were observed.
- 25 October 2024
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 28 (6) , 763-772
Safety and efficacy of sodium benzoate for patients with mild Alzheimer’s disease: a systematic review and meta-analysis
Alzheimer's disease (AD) is the most common neurodegenerative disorder. A key factor in its pathogenesis is the dysfunction of the N-methyl-D-aspartate (NMDA) receptor due to D-serine degradation by D-amino acid oxidase. Benzoate has been suggested to enhance NMDA receptor function, potentially benefiting early-phase AD. This study aimed to synthesize evidence from randomized clinical trials (RCTs) on the safety and efficacy of sodium benzoate in AD patients. We followed PRISMA statement guidelines during the accommodation of this systematic review and meta-analysis. A computer literature search (PubMed, Scopus, Web of Science, and Cochrane Central) was conducted. We included RCTs that compared sodium benzoate with placebo regarding cognitive functions. The primary outcome measure was the Alzheimer's disease assessment scale-cognitive subscale, pooled as the mean difference between the two groups from baseline to the endpoint. The secondary outcomes measures are the clinician's interview-based impression of change plus caregiver input, catalase, and superoxide dismutase antioxidants. Three RCTs (described in four articles) with 306 patients were included in this study. Sodium benzoate significantly improved the ADAS-cog score compared with placebo (MD -2.13 points, 95% CI [-3.35 to -0.90]; P= 0.0007). Sodium benzoate is a safe drug that may improve cognitive function in patients with early-stage Alzheimer's disease. However, the significant effect arises primarily from one small study, highlighting the need for caution in interpretation. Further research with larger sample sizes and longer durations is necessary to validate these findings and assess safety and efficacy.
- 25 October 2024
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 28 (6) , 763-772
Safety and efficacy of sodium benzoate for patients with mild Alzheimer’s disease: a systematic review and meta-analysis
Alzheimer's disease (AD) is the most common neurodegenerative disorder. A key factor in its pathogenesis is the dysfunction of the N-methyl-D-aspartate (NMDA) receptor due to D-serine degradation by D-amino acid oxidase. Benzoate has been suggested to enhance NMDA receptor function, potentially benefiting early-phase AD. This study aimed to synthesize evidence from randomized clinical trials (RCTs) on the safety and efficacy of sodium benzoate in AD patients. We followed PRISMA statement guidelines during the accommodation of this systematic review and meta-analysis. A computer literature search (PubMed, Scopus, Web of Science, and Cochrane Central) was conducted. We included RCTs that compared sodium benzoate with placebo regarding cognitive functions. The primary outcome measure was the Alzheimer's disease assessment scale-cognitive subscale, pooled as the mean difference between the two groups from baseline to the endpoint. The secondary outcomes measures are the clinician's interview-based impression of change plus caregiver input, catalase, and superoxide dismutase antioxidants. Three RCTs (described in four articles) with 306 patients were included in this study. Sodium benzoate significantly improved the ADAS-cog score compared with placebo (MD -2.13 points, 95% CI [-3.35 to -0.90]; P= 0.0007). Sodium benzoate is a safe drug that may improve cognitive function in patients with early-stage Alzheimer's disease. However, the significant effect arises primarily from one small study, highlighting the need for caution in interpretation. Further research with larger sample sizes and longer durations is necessary to validate these findings and assess safety and efficacy.